Table 2.
Univariate analysis of predictors for disease-free survival.
| Variables | HR (95% CI) | p Value |
|---|---|---|
| Age | 1.02 (0.98–1.06) | 0.402 |
| Male gender | 1.02 (0.45–2.33) | 0.957 |
| Current/former smoking | 0.70 (0.26–1.86) | 0.472 |
| Upper/middle lobe | 1.68 (0.65–4.31) | 0.282 |
| Surgical extent 1 | ||
| Wedge resection | 2.47 (0.98–6.23) | 0.057 |
| Segmentectomy | 0.76 (0.26–2.25) | 0.618 |
| Adjuvant treatment | 1.30 (0.44–3.83) | 0.636 |
| Stage IB | 1.69 (0.65–4.40) | 0.283 |
| Neutrophil percentage | 1.04 (1.00–1.09) | 0.055 |
| Lymphocyte percentage | 0.98 (0.94–1.02) | 0.281 |
| NLR | 0.99 (0.91–1.07) | 0.740 |
| Histology | ||
| Adenocarcinoma 2 | 1.21 (0.16–9.06) | 0.851 |
| Histological grade 3 | ||
| Well-differentiated | 0.43 (0.10–1.93) | 0.269 |
| Moderately differentiated | 0.45 (0.09–2.18) | 0.321 |
| IASLC grading 4 | ||
| Grade 1 | 0.31 (0.11–0.90) | 0.031 |
| Grade 2 | 0.36 (0.11–1.26) | 0.110 |
1 lobectomy used as the reference; 2 squamous cell carcinoma used as the reference; 3 poorly differentiated used as the reference; 4 Grade 3 used as the reference; CI, confidence interval; HR, hazard ratio; IASLC, International Association for the Study of Lung Cancer; NLR, neutrophil-to-lymphocyte ratio.